Sarepta price target raised to $223 from $215 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Sarepta Therapeutics to $223 from $215 and keeps a Buy rating on the shares. The FDA broadened the label for Elevidys in Duchenne muscular dystrophy from the accelerated approval in ambulatory 4-5 year-olds to include ambulatory and non-ambulatory patients at least four years old via traditional and accelerated approval, the analyst tells investors in a research note. The firm expects continued execution on the launch and remains positive on Sarepta’s outlook. It models for peak Elevidys revenue of $2.6B in 2028.